

No.	Title	First Name	Last Name	Affiliation	Country
1	The Impact of the 2009 Influenza Pandemic on the Seasonality of Human Respiratory Syncytial Virus: a Systematic Analysis	You	Li	University of Edinburgh	United Kingdom
2	Viral Detection and Identification in 20 minutes by Rapid Single-particle Fluorescence In-situ Hybridization of Viral RNA	Christof	Hepp	University of Oxford	United Kingdom
3	Seroprevalence of SARS-CoV-2 in Three Communities in South Africa During and After the Second Wave: a Cross-sectional Household Survey	Nicole	Wolter	National Institute for Communicable Diseases	South Africa
4	Timing of Seasonal Influenza Epidemic Activity in Africa during 2010 to 2019 - Using National Surveillance Systems to Guide Vaccine Preparedness	Ledor	Igboh	Centers for Disease Control and Prevention	United States
5	Incidence and Positivity of COVID-19 Tests in an Educational Community of Public Schools of the City of Bogotá in 2020	Jose	Moreno	Fundación Santa Fe de Bogotá	Colombia
6	Surveillance Studies for Influenza A Viruses at the Human-Animal Interface in South Africa	Mohamed Ezzat	El Zowalaty	Uppsala University	Sweden
7	Impact Of COVID-19 Outbreak on the Circulation Patterns of Seasonal Respiratory Viruses In Madagascar	Norosoa	Razanajatovo	Institut Pasteur	Madagascar
8	Seasonality Methods Used to Determine the Timing of RSV Epidemics: A Systematic and Comparative Review	Lisa	Staadegaard	NIVEL	Netherlands
9	Increased Risk of Rhinovirus Infection in Children During the COVID-19 Pandemic	Emi	Takashita	National Institute of Infectious Diseases	Japan
10	Development and Validation of a Rapid, Cost Effective Loop Mediated Isothermal Amplification Assay to Detect Severe Acute Respiratory Syndrome Corona virus-2	Bushran	Noor	University of Peradeniya	Sri Lanka
11	RSV Surveillance in Chile 2019-2021	Alejandra	Acevedo	Institute of Public Health	Chile
12	Low Circulation of Influenza Virus Among SARS CoV-2 Infection Suspected Patients During the Ongoing Covid-19 Pandemic in Central Province of Sri Lanka	Shiyamalee	Arunasalam	University of Peradeniya	Sri Lanka
13	Influenza-Associated Severe Acute Respiratory Infection in Patients Below 14 Years in Maputo, Mozambique, 2017-2018	Felix Alberto	Gundane Albati	Instituto Nacional de Saúde	South Sudan
14	Off-season RSV Epidemics in Australia After Easing of COVID-19 Restrictions	John-Sebastian	Eden	The University of Sydney	Australia
15	SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran	Zahra	Heydarifard	Tehran University of Medical Sciences	Iran, Islamic Republic of
16	Molecular Epidemiology of SARS-CoV-2 in Lebanon	Sima	Tokajian	Lebanese American University	Lebanon
17	Community Mortality due to RSV in Children Under 5: Active Surveillance Study Based on Tissue Sampling	Mauricio	Caballero	Fundacion Infant	Argentina
18	Plans to Create and Publish a Fortnightly Electronic Bulletin on RSV Activity in Europe and the Establishment of a European Laboratory Network for RSV	John	Paget	Netherlands Institute for Health Services Research (NIVEL)	Netherlands
19	Estimating Transmissibility of Asymptomatic Influenza Virus Infections	Tim K.	Tsang	The University of Hong Kong	Hong Kong SAR, China
20	Local Patterns of Spread of Influenza A(H3N2) Virus in Coastal Kenya Over a One-Year Period Revealed Through Virus Sequence Data	David Collins	Owuor	Kenya Medical Research Institute	Kenya
21	Household Transmission Dynamics of Influenza A Virus Infection and its Implication of Vaccine Strategy	Tim K.	Tsang	The University of Hong Kong	Hong Kong SAR, China
22	Reconstructing Antibody Dynamics to Estimate the Risk of Influenza Infection	Tim K.	Tsang	The University of Hong Kong	Hong Kong SAR, China
23	Evaluating the Existence of Seasonality of Influenza Incidence in Vietnam	Joseph	Servadio	Pennsylvania State University	United States
24	Reassortant of H1N1 Swine Influenza Virus in Siberia Region, Russia	Ivan	Sobolev	Federal Research Center of Fundamental and Translational Medicine	Russian Federation
25	Clinical and Economic Impact of COVID-19 on Plantation Workers: Preliminary Results from the Guatemala Agricultural Workers and Respiratory Illness Impact (AGRI) Study	Daniel	Olson	University of Colorado School of Medicine	United States
26	Comparisons of RSV and Influenza: Population Characteristics and Clinical Outcomes in Hospitalized Adults	Katherine	Miller	University of Michigan	United States
27	Out-of-season Circulation of Seasonal Respiratory Viruses in the Netherlands During the COVID-19 Pandemic	Anne	Teirlinck	National Institute for Public Health and the Environment (RIVM) - Centre for Infectious disease control, Bilthoven	Netherlands
28	Transmission of SARS-CoV-2 Within Households: a Case-ascertained Study	Carlos	Grijalva	Vanderbilt University Medical Center	United States

29	Serosurveillance of Sars-Cov-2 Antibody Post Vaccination and Infection in Indonesia 2020-2021	Reviany Vibrianita	Nidom	Professor Nidom Foundation	Indonesia
30	Clinical and Economic Burden of Seasonal Influenza in Indonesia, Thailand and Vietnam - A Systematic Review	See Hwee	Yeo	IQVIA	Singapore
31	Comparing the Universal Community Nucleic Acid Testing with Existing Clinical and Public Health Surveillance in Hong Kong Reveals Insights into COVID-19 Transmission Dynamics	Bingyi	Yang	The University of Hong Kong	Hong Kong SAR, China
32	Surveillance of SARS-CoV-2 Infection in Dogs and Cats in the Department of Córdoba, Colombia	Yesica	Botero	Universidad de Córdoba	Colombia
33	SeroTracker-ROB: an Approach to Expediting Risk of Bias Assessments for Seroprevalence Studies	Niklas	Bobrovitz	University of Toronto	Canada
34	SARS-CoV-2 in Danish Mink and the Association with Occupational Risk and Community Cases in Denmark in 2020	Helle	Larsen	Statens Serum Institut	Denmark
35	Sentinel Surveillance of ILI, ARI and COVID-19 in Season 2020/2021 in Slovenia	Maja	Socan	NIPH	Slovenia
36	Characterizing the Seasonality of Respiratory Syncytial Virus in Guatemala, 2010-2018	Sarah	Hamid	Emory University	United States
37	Clinical and Epidemiological Features of Patients Hospitalized with COVID-19 during the Various Periods of the Epidemic in Moscow	Vladimir	Korshunov	I.M. Sechenov First Moscow State Medical University, Institution of Public Health	Russian Federation
38	Assessing the Effect of Restaurant-based Measures on the Transmission of COVID-19 in Hong Kong	Faith	Ho	University of Hong Kong	Hong Kong SAR, China
39	AFRO-MoVE: Establishment of the First African Network to Monitor Vaccine Effectiveness for COVID-19 and other Respiratory Pathogens	Celine	Gurry	Epiconcept	France
40	Severity of SARS-CoV-2 Infection During the First Wave in the Netherlands	Pieter	de Boer	National Institute for Public Health and the Environment (RIVM)	Netherlands
41	Evaluation of the National Disease Surveillance System for COVID-19, Egypt, 2020	Walaa	Attia	Ministry of Health and Population	Egypt
42	Assessment of Risk Factors for SARS-CoV-2 Infection Among Health Care Workers in India: A Case Control Study	Chitra	Tomy	Community Medicine, Amrita School of Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala	India
43	Unusual Out-of-season RS-virus Activity in 2021 in Denmark	Ramona	Trebbien	Statens Serum Institut	Denmark
44	Evaluation of Egypt Event-Based Surveillance System as an Early Warning for COVID-19, Egypt, 2021	Mohamad	Fawzy Salem	Ministry of Health and Population	Egypt
45	Economic Burden of Seasonal Influenza in Mainland China From 2011 to 2019	Chen	Chen	PKU China Center for Health Economic Research	China
46	Patient Characteristics of COVID-19 Cases in Seven European Countries: One Year of Surveillance in the I-MOVE-COVID-19 Primary care/outpatient Surveillance network	Tessa	Jansen	Netherlands Institute for Health Services Reseach (NIVEL)	Netherlands
47	Assessing and Communicating the Impact of SARS-CoV-2 on Influenza Activity: the FluCov EpiBulletin	Sytske	Wiegersma	Netherlands Institute for Health Services Research (Nivel), Utrecht	Netherlands
48	Hemagglutination Inhibition Antibody Response Following Influenza A(H3N2) Virus Natural Infection	Anup	Jayaram	Manipal Institute of Virology	India
49	Phylogenetic Inference of SARS-CoV-2 Case Counts and Early Spread in Europe from Genetic Sequences	Cecilia	Valenzuela Agui	ETH Zurich D-BSSE	Switzerland
50	Coincident Rapid Expansion of two SARS-CoV-2 Lineages with Enhanced Infectivity in Nigeria	Judd	Hultquist	Northwestern University	United States
51	Whole Genome Sequencing of Influenza A & B Viruses Using the Illumina Miseq Platform	Taylor	Dean	Division of Infectious Diseases, Northwestern University Feinberg School of Medicine	United States
52	Epidemiological Characteristics of COVID-19 Patients, Sahel District, Cairo, 2020	Neven	Girgis	Ministry of Health & Population-FETP Egypt	Egypt
53	K-Medoids Clustering of Hospital Admission Characteristics to Classify Severity of Influenza Infection	Aleda	Leis	University of Michigan	United States
54	A Comparative Analysis of the Epidemiology of Influenza and RSV in Russia: Data from a Large and Diverse Country in Europe	Saverio	Caini	Netherlands Institute for Health Services Research (NIVEL)	Netherlands
55	Quantification of Respiratory Virus RNA in Aerosols in Pediatric Patient Rooms	Yanmin	Xie	School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong	Hong Kong SAR, China
56	Quantification of Common Respiratory Viruses in Aerosols in Pediatric Patient Rooms	Yanmin	Xie	School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong	Hong Kong SAR, China
57	Incidence of Acute Lower Respiratory Infections due to Respiratory Syncytial Virus in Young Children in South Asia: a Systematic Review and Meta-analysis	Jessy	Joseph	IAVI	India

58	Respiratory Syncytial Virus Among Under-five Children with Acute Respiratory Infection Attending Health Care Facilities in India: a Systematic Review and Meta-analysis	Ruchita	Jalal	IAVI-India	India
59	20 Months of COVID-19 Pandemic Response and Genomic Data Sharing Through GISAID	Celine	Gurry	GISAID	Norway
60	INSAFLU-TELE-Vir: an Open Web-based Bioinformatics Suite for Genome-based Surveillance of Influenza, SARS-CoV-2 and Other Pathogens	Vitor	Borges	National Institute of Health Dr. Ricardo Jorge (INSA)	Portugal
61	Virus Surveillance with CoVsurver, FluSurver and RSVsurver	Raphael Tze Chuen	Lee	Bioinformatics Institute (BII)	Singapore
62	Systematic Review and Meta-analysis of SARS-CoV-2 in Household and First Few X Case Transmission Investigations Aligned With WHO's UNITY Guidance	Isabel	Bergeri	WHO HQ	Switzerland
63	Genomic Surveillance of SARS-CoV-2 In Argentina	Elsa Graciela	Baumeister	INEI ANLIS Carlos G Malbrán	Argentina
64	External Quality Assessment 2020 of Influenza Virus Diagnostics and Characterization by National Influenza Centres in the WHO European Region	Adam	Meijer	National Institute for Public Health and the Environment (RIVM)	Netherlands
65	Molecular Epidemiology of the COVID-19 Pandemic in Chicago	Ted	Ling Hu	Northwestern University	United States
66	Seasonal Influenza Vaccination Coverage Among Pregnant Women in the Afro Region: Systematic Review	Ghada Essam El-Din	Amin	Department of Family Medicine, Faculty of Medicine, Ain Shams University	Egypt
67	Population-Level Surveillance for COVID-19: An Effective Approach for Infection Prevention	Christina	Mack	IQVIA	United States
68	Estimating COVID-19 Hospitalizations in the United States with Surveillance Data Using a Bayesian Hierarchical Model	Alexia	Couture	Centers for Disease Control and Prevention	United States
69	SARS-CoV-2 Seroprevalence in the WHO Africa Region: a Systematic Review and Meta-analysis of SARS-CoV-2 Seroprevalence Studies Aligned with the WHO Population-based Sero-epidemiological Study Protocol ('Unity Studies')	Hannah	Lewis	WHO HQ	Switzerland
70	Immunoassays Used in SARS-CoV-2 Seroprevalence Surveys Worldwide: a Descriptive Analysis of Assay Use, Testing Algorithms, and Performance	Zihan	Li	University of Waterloo	Canada
71	The Sensitivity and Specificity of a Rapid Diagnostic Test for RSV in Children Hospitalized at a Laboratory-Resource Limited Setting in Amman, Jordan	Ahmad	Yanis	Vanderbilt University Medical Center	United States
72	SARS-CoV-2 Global and Regional Seroprevalence: a Systematic Review and Meta-analysis of Population-Based Sero-Epidemiological Studies Aligned with the WHO UNITY Protocol	Isabel	Bergeri	World Health Organization HQ	Switzerland
73	The Effectiveness of COVID-19 Serosurveys as Surveillance Tools: Measuring Timeliness, Data Quality, and Representativeness	Natasha	Ilincic	University of Toronto	Canada
74	Stored Samples for Serosurveillance: are Banked Blood and Residual Sera Suitable Proxies for the General Population? A Meta-regression Analysis	Christian	Cao	Cumming School of Medicine, University of Calgary, Calgary, Alberta	Canada
75	Molecular Epidemiology of SARS-CoV-2 from March/2020 to August/2021 in a Tertiary Hospital In Southern Brasil	Bruna	Lapinski	Universidade Federal do Paraná	Brazil
76	Respiratory Syncytial Virus Diversity Influencing Host-Pathogen Response and Clinical Outcomes in Hospitalized Adult Populations	Estefany	Rios Guzman	Northwestern University	United States
77	Estimation of SARS-CoV-2 Global and Regional Seroprevalence Over Time	Harriet	Ware	Centre for Health Informatics, Cumming School of Medicine, University of Calgary	Canada
78	SARS-CoV-2 Variant Surveillance During the Second Wave in Argentina Reflects the South America Scenario: High Prevalence of Gamma and Lambda	Carolina	Torres	Universidad de Buenos Aires	Argentina
79	The Change in Pediatric Hospitalization for Acute Respiratory Infections Associated with RSV in COVID-19 Era in Vietnam	Hirono	Otomaru	Nagasaki University	Japan
80	Genetic Characterization and Circulation Pattern of Respiratory Syncytial Virus (RSV) in Children with a Respiratory Infection, Tehran, Iran, during 2018-2019	Forough	Tavakoli	Tehran University of Medical Sciences	Iran, Islamic Republic of
81	Setting Outpatient Respiratory Infection Sentinel Surveillance System, Lebanon, Nov 2020-Aug 2021	Nada	Ghosn	Ministry of Public Health	Lebanon
82	History of Avian Influenza in Libya	Ibrahim	Eldaghayes	Faculty of Veterinary Medicine	Libya
83	Mutant Viral Strains and Clinical Characteristics of SARS-CoV-2 Infected (COVID-19) Patients in Rural Area of Japan	Masafumi	Seki	Tohoku Medical and Pharmaceutical University	Japan
84	Canine Coronavirus in Nigeria: a Missed Diagnosis or an Under-reported Zoonotic?	Okoli	Solomonchieloka	Federal Ministry of Agriculture and Rural Development Ebonyi	Nigeria
85	Detection of Multiple Respiratory Viruses Among SARS-CoV-2 Positive and SARS-CoV-2 Negative Patients by Multiplex TaqMan One-Step Real Time PCR	Somayeh	Shatizadeh Malekshahi	Tarbiat Modares University	Iran, Islamic Republic of
86	Interactions Between SARS-CoV-2 and Influenza A(H1N1)pdm09 Viruses in Human Epithelial Nasal Cells	Clement	Fage	CHU de Quebec-Université Laval	Canada
87	Bacterial Superinfection Induces a Major Transcriptional Regulatory Switch of Interferon Stimulated Genes	Justine	Oliva	CIRI (Centre International de Recherche en Infectiologie) - Team VirPath	France

88	The Pandemic has Affected Co-infections for some Respiratory Pathogens but not Others: Results from a Clinical Audit of a Singapore Teaching Hospital	Vennila	Gopal	National University of Singapore	Singapore
89	Incidence of COVID-19 Among International Travelers from Egypt, March-October2020	Abeer	Abdelaziz	Central Public Health Laboratories	Egypt
90	Detection of other Respiratory Viruses by RT-PCR in SARI Patients During September 2020 to January 2021, With Circulation of Covid-19	Patricia	Bustos	Public Health Institute	Chile
91	High Resolution Analysis of Respiratory Syncytial Virus Infection in Vivo	Waleed	Aljabr	King Fahad Medical City, Research Center	Saudi Arabia
92	Codon-Pair Biases in Influenza, RSV and Coronavirus Genomes	Ewan P.	Plant	Food and Drug Administration	United States
93	Identifying Amino Acid Substitutions Involved in the Zoonotic Transmission of the 2009 Pandemic H1N1 Using Phylogenetic and Ancestral Inference Analysis	Klara Marie	Andersen	Statens Serum Institut	Denmark
94	Limited Within-host Diversity and Tight Transmission Bottlenecks Limit SARS-CoV-2 Evolution in Acutely Infected Individuals	Katarina	Braun	University of Wisconsin-Madison	United States
95	Evolution of SARS-CoV-2 Variants of Concern Under In Vitro Neutralising Selection Pressure Following Two Doses of Pfizer/BioNTech (BNT162b2) Vaccination in Australian Healthcare Workers	Kerri	Basile	Centre for Infectious Diseases and Microbiology Laboratory Services - ICPMR - NSW Health Pathology	Australia
96	Case-ascertained Study of SARS-CoV-2 Among Households in Southeast Michigan	Johnny	Uelmen	University of Michigan	United States
97	Genetic Characterization and Evolution of The Avian Influenza H9N2 in Broiler Chicken in Indonesia 2011-2018	Setyarina	Indrasari	Professor Nidom Foundation	Indonesia
98	Severe Cases of Seasonal Influenza and Evaluation of A(H1N1)pdm09 HA-222D/G/N polymorphism in Russia in 2019-2020	Natalia	Kolosova	FBRI SRC VB Vector	Russian Federation
99	The Impact of Hospital Isolation on the Evolution of Case Fatality Rate	M. Pear	Hossain	City University of Hong Kong	Hong Kong SAR, China
100	Description of Possible Events of Intrahospital Circulation of SARS-CoV-2 in a University Hospital in Buenos Aires City, 2021	Andrea	Pontoriero	Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza OMS, INEI-ANLIS "Dr. Carlos G. Malbrán"	Argentina
101	2019 Influenza Season in Maputo City: Unnoticed Outbreak?	Judite	Salencia-Ferrao	Instituto Nacional de Saude	Mozambique
102	The Evolution and Genetic Characterization of Low Pathogenic Avian Influenza H9N2 Viruses in India	Deeksha	Tare	ICMR-National Institute of Virology, Pune	India
103	Transmission Dynamics of Low Pathogenicity Avian Influenza (H2N2) Viruses in Live Bird Markets of the Northeast United States of America, 2014-2019	Hyunjung	Chung	University of Connecticut	United States
104	A Prospective Study of Secondary Attack Rate and Risk Factors Among Contacts of Covid Positive Patient at the Household Level in Kerala	Aswathy	Sreedevi	Amrita Institute of Medical Sciences	India
105	Antibodies Elicited by COVID-19 mRNA Vaccines Neutralize Variants of Concern and Variants of Interest	Li	Wang	Centers for Disease Control and Prevention	United States
106	Characterization of Antibody Response in Asymptomatic and Symptomatic SARS-CoV-2 Infection	Serena	Marchi	University of Siena	Italy
107	2-photon Microscopy Analysis Reveals Differential Pulmonary Damages after Infection by Influenzavirus and SARS-CoV-2	Frédéric	Rivière	IRBA	France
108	Contribution of 2-photon microscopy (2PM) for exploration of immune mechanisms after Influenza infection of mice model.	Frédéric	Rivière	IRBA	France
109	IL-6, IL-8 and IFN- $\beta$ are Elevated in Individuals with Long COVID	Jane	Sinclair	The University of Queensland, School of Chemistry and Molecular Biosciences	Australia
110	T Cellular and Serological Immune Responses in SARS-CoV-2 Infected Children	Carolyn	Cohen	HKU-Pasteur, University of Hong Kong	Hong Kong SAR, China
111	Assessment and Modeling of COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults	Lacy	Simons	Northwestern University Feinberg School of Medicine	United States
112	Monitoring the Progression of SARS-CoV-2 Infection in Patients by Molecular Diagnostics and Self-Reported Symptoms	Gaston	Bonenfant	Centers for Disease Control and Prevention	United States
113	Viral Shedding and Infection Outcomes in Symptomatic COVID-19 Patients	Yun	Lin	School of Public Health, LKS Faculty of Medicine, University of Hong Kong	Hong Kong SAR, China
114	EMPATHY: Ph2-3 Randomized, Placebo-Controlled Trial Evaluating Safety and Efficacy of Ensovibep in Ambulatory COVID-19 Patients	Marianne	Soergel	Molecular Partners AG	Switzerland
115	Activity of PB2 Polymerase Inhibitor Pimodivir Against Human and Animal-origin Influenza A Viruses	Mira	Patel	Centers for Disease Control and Prevention	United States
116	Inhibition of Respiratory Syncytial Virus Infectivity by Traditional Herbal Medicine, Maoto, through Interaction with G Glycoprotein	Shigeki	Nabeshima	General Medicine, Fukuoka Uni Hospital	Japan
117	Discovery of Pan-ErbB Inhibitors Protecting from SARS-CoV-2 Replication, Inflammation, and Lung Injury by a Drug Repurposing Screen	Sirle	Saul	Stanford University	United States

118	Dose-ranging Virology study of the Combination COVID-19 Antibodies Casirivimab and Imdevimab (cas/imd) in the Outpatient Setting	Cynthia	Portal-Celhay	Regeneron Pharmaceuticals, Inc.	United States
119	Intranasal Fusion Inhibitory Lipopeptide Prevents Direct Contact SARS-CoV-2 Transmission in Ferrets	Anne	Moscona	Columbia University Vagelos College of Physicians and Surgeons	United States
120	EDP-235, A Potential Oral, Once-daily Antiviral Treatment and Preventative for COVID-19	Li-Juan	Jiang	Enanta Pharmaceuticals, Inc.	United States
121	Effects of Medical Fraud and Bias on the Clinical Efficacy of Ivermectin	Manya	Mirchandani	Imperial College London	United Kingdom
122	Inhibition of Influenza type A, B, and C virus Replication by Polymerase Inhibitors Baloxavir, AV5116, and AV5115 Using the High Content-imaging Neutralization (HINT) Assay	Anton	Chesnokov	Centers for Disease Control and Prevention (US)	United States
123	Anti-Influenza Immunoglobulin (FLU-IGIV) in Hospitalized Patients with Serious Influenza A	Amy	Dahl	Emergent BioSolutions Inc	Canada
124	Clinical Impact of Concomitant Use of a Novel High-Titer Immune Globulin in an Adult with COVID-19 and Severe Acute Respiratory Distress Syndrome (ARDS)	Gene	Wetzstein	ADMA Biologics	United States
125	Silmitasertib in the Treatment of Patients with Moderate COVID-19: An Open-label, Randomized, Phase 2 Trial	Joanne	Lo	Senhwa Biosciences Inc.	Taiwan
126	Convenient Reporter Assay to Monitor Influenza Virus HA-mediated Fusion, Develop Fusion Inhibitors and Determine the HA Fusion pH	Silke	Rimoux	Rega Institute, KU Leuven, Leuven, Belgium	Belgium
127	Pre-clinical Development of Novel Small Molecule Inhibitors of Respiratory Syncytial Virus replication	Elaine	Thomas	ReViral Ltd	United Kingdom
128	In Depth Study of the Carbohydrate-Binding Agents HHA, GNA and UDA as Potent Inhibitors of Influenza A and B Virus Replication	Evelien	Vanderlinden	Rega Institute for Medical Research	Belgium
129	Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants in Vitro and in Early Clinical Studies	Jay	Grobler	Merck & Co., Inc.	United States
130	Broad and Potent in Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life-Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19	Chengzi	Kaku	Adimab LLC	United States
131	Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life-Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study	Pete C.	Schmidt	Adagio Therapeutics, Inc.	United States
132	Weak Neutralizing Activity of Antibodies Binding to a Conserved Region of the Coronavirus Fusion Peptide	Nathalie	Vanderheijden	Ghent University	Belgium
133	Heterogeneity of Treatment Effect of Interferon $\beta$ 1b and Lopinavir/Ritonavir in Patients with Middle East Respiratory Syndrome by Cytokine Levels and Timing of Therapy	Yaseen	Arabi	King Abdulaziz Medical City	Saudi Arabia
134	Pharmacokinetics of Sotrovimab, a Monoclonal Antibody for Early Treatment of Mild-to-Moderate COVID-19	Jennifer	Sager	Vir Biotechnology, Inc.	United States
135	Remdesivir Retains Potent Antiviral Activity Against the SARS-CoV-2 Delta Variant and Other Variants of Concern	Jared	Pitts	Gilead Sciences, Inc.	United States
136	AT-527 Achieves Antiviral Concentrations in the Human Lung	Xiao-Jian	Zhou	Atea Pharmaceuticals, Inc	United States
137	Pleiotropic Effects of Potential Baloxavir Resistance-Associated Substitutions	Brady	Hickerson	Division of Biotechnology Review and Research II, Food and Drug Administration	United States
138	Fitness & Baloxavir Susceptibility of Influenza Viruses Bearing PA E32G/K or E23G/K Plus I38T	Jeremy	Jones	St. Jude Children's Research Hospital	United States
139	In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance	Guy	Boivin	CHU de Quebec-Université Laval	Canada
140	Surveillance for Antiviral Resistance Among Influenza Viruses Circulating in Chile: a Retrospective Study (2015-2020)	Gabriel	Leal	Public Health Institute of Chile	Chile
141	Evaluating the BNT162b2 Vaccine Efficacy Against SARS-CoV-2 Variants of Concern	Michal	Manldeboim	Tel Hashomer Hospital	Israel
142	Comparison of Amplicon-Based Conventional and Long-read Illumina Sequencing for Detection of Minority Variants with Likely Resistance to Neuraminidase Inhibitors in a Clinical Samples	Temitope	Faleye	Arizona State University	United States
143	Genomic Analysis of Patient Viral Samples from the Remdesivir Phase 3 Severe and Moderate COVID-19 SIMPLE Trials	Charlotte	Hedskog	Gilead Sciences	United States
144	Self-amplifying mRNA SARS-CoV-2 Vaccines Raise Cross-reactive Immune Response to Variants and Prevent Infection in Animal Models	Yingxia	Wen	Seqirus	United States
145	Sa-mRNA Influenza Vaccines Co-express HA and NA Antigens and Raise Neutralizing Antibody and Cell Mediated Immune Responses in Mice	Yingxia	Wen	Seqirus	United States
146	A Novel Hapten-Modified SARS-Cov-2 Spike Protein Vaccine Induces Antibody and T Cell Responses in a Murine Model	David	Berd	Biovaxys Technology Corp.	Canada
147	OVX836, Np-Based Universal Influenza Vaccine Candidate: Results of Phase 2a Clinical Trial	Delphine	Guyon-Gellin	Osivax	France
148	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model	Jeffrey	Loube	Johns Hopkins University	United States
149	Antibody Immunity to SARS-CoV-2 by Infection and Vaccination	Sophie	Valkenburg	The University of Hong Kong	Hong Kong SAR, China
150	COVID-19 Vaccinations in Pregnancy: A Comparative Evaluation of Acute Side Effects and Impact on Quality of Life Between Pregnant and Non-pregnant Women in the US	Emma	Brinkley	IQVIA	United States
151	A Real-World Comparison Between Adjuvanted Trivalent Influenza Vaccine and Trivalent High-Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2019-20 Season Among U.S. Elderly	Joaquin	Mould	Seqirus	United States

152	Relative Effectiveness of MF-59-adjuvanted, Trivalent Influenza Vaccine vs Quadrivalent Influenza Vaccine and High-dose Trivalent Influenza Vaccine in Preventing Influenza-Related Medical Encounters in Adults During the 2019-2020 Influenza Season in the United States	Tina	Boikos	Seqirus	Canada
153	Relative Effectiveness of Cell Derived Quadrivalent Influenza Vaccine Versus Egg Derived Quadrivalent Influenza Vaccine in Preventing Influenza Related Medical Encounters in a Pediatric Population During the 2019-2020 US Influenza Season	Tina	Boikos	Seqirus	Canada
154	Relative Effectiveness of Cell Derived Quadrivalent Influenza Vaccine Versus Egg Derived Quadrivalent Influenza Vaccine in Preventing Influenza Related Medical Encounters in Adults During the US 2019-2020 Influenza Season	Tina	Boikos	Seqirus	Canada
155	Cost-effectiveness of an MF59-adjuvanted Quadrivalent Influenza Vaccine Compared to High and Standard-dose Quadrivalent Influenza Vaccines in Germany	Joaquin	Mould	Seqirus	United States
156	Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Versus Egg-Based High-Dose Trivalent Influenza Vaccine in Older Adults During the 2019-20 Influenza Season in the US	Joaquin	Mould	Seqirus	United States
157	Relative Vaccine Effectiveness of Cell-Based vs Egg-Based Quadrivalent Influenza Vaccines Against Influenza-Related Hospitalizations and Respiratory Events in Children and Adults in the US During the 2019-20 Influenza Season	Joaquin	Mould	Seqirus	United States
158	Safety and Tolerability of an Ad26.RSV.preF-based Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study in Adults Aged 65 Years or Older	Ann	Falsey	University of Rochester School of Medicine	United States
159	A Research and Development (R&D) Roadmap for Influenza Vaccines	Josie	Golding	Wellcome	United Kingdom
160	A Single Vaccine Induces Broad-Spectrum Neutralizing Ab Against SARS-CoV-2 and Protects Against SARS-CoV-2 and Influenza Virus in Mice	Kangli	Cao	Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University	China
161	Variations in Non-Pharmaceutical Interventions by State Correlate with COVID-19 Disease Outcomes	Seema	Lakdawala	University of Pittsburgh School of Medicine	United States
162	Suppression of an Outbreak of COVID-19 Without Lockdown	Hsiang-Yu	Yuan	City University of Hong Kong	Hong Kong SAR, China
163	Warm Temperature and High Humidity Exposure Around Symptom Onset are Associated with COVID-19 Disease Severity	Jingbo	Liang	City University of Hong Kong	Hong Kong SAR, China
164	Knowledge, Attitude, and Practices Towards Spread, Risk, Prevention Measures and Vaccination of COVID-19 Among Students in Afghanistan	Said Iftexhar	Sadaat	Swedish Committee for Afghanistan	Afghanistan
165	Breadth: Attitude and Behavior of Emerging Novel COVID-19 Disease Khartoum, Sudan	Elamin	Abualas	National Public Health Laboratory	Sudan
166	Pandemic Fatigue and Attenuated Impact of Public Health and Social Measures Against COVID-19 Transmission in Hong Kong by Cross-Sectional Telephone Surveys	Huizhi	Gao	The University of Hong Kong	Hong Kong SAR, China
167	The Effectiveness of an Online Health Education Programme for Young Primary School Students to Prevent COVID-19 Infection in Hong Kong	Yiyang	Guo	School of Public Health, The University of Hong Kong	Hong Kong SAR, China
168	SARS-CoV-2 Inactivation by Ultraviolet Radiation and Visible Light: an Evaluation of the Effects of 16 Different Wavelengths in Wet and Dried Samples	Michael	Schuit	National Biodefense Analysis and Countermeasures Center	United States
169	Non Pharmacological Interventions Reduce the RSV Hospital Burden in the Elderly During the 2020/2021, Respiratory Syncytial Virus Epidemic, Rhône Loire, France	Jean-sebastien	Casalegno	Hospices Civils de Lyon	France
170	Prioritization of School-Based Control Measures for Intervention Studies	Min Whui	Fong	School of Public Health, University of Hong Kong	Hong Kong SAR, China
171	Influenza A Disease Severity: Proposition of a Prognostic Score	Bruna	Lapinski	Federal University of Paraná	Brazil
172	Isolation Practices and Household Transmission of SARS-CoV-2 at Two US Sites	Alexandra	Mellis	Centers for Disease Control and Prevention	United States
173	Influenza A Viral Load is Associated With Disease Severity - A Retrospective Cross-Sectional Study in a Tertiary Hospital In Southern Brazil	Bruna	Lapinski	Universidade Federal do Paraná	Brazil
174	Modeling Operational Interventions Within Refugee and IDP Settlements: A Scenario-Based Case Study of COVID-19 in Spread in the Cox's Bazar Settlement	Joseph	Aylett-Bullock	United Nations Global Pulse	United States
175	Using Gargle for Diagnosing SARS-CoV-2 Infection Among Suspected Individuals	Nicole Ngai Yung	Tsang	WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.	Hong Kong SAR, China
176	Ready2Respond: New Opportunities for Supporting Influenza and Pandemic Readiness in LMICs	Marie	Mazur	Ready2Respond ( based at The Task Force for Global Health)	United States

177	Pandemic Preparedness, Have We Got It Right?	William	Cracknell	Independent Consultant	Australia
178	Bringing Evidence to the Bedside in Real-Time via Mobile Application: Coordinated dissemination of World Health Organization Guidelines and Trainings on COVID-19 Therapeutics	Pryanka	Relan	World Health Organization	Switzerland
179	Change of Predictors of COVID-19 Vaccine Hesitancy Over Time Among Adults in Hong Kong	Jingyi	Xiao	The University of Hong kong	Hong Kong SAR, China
180	Early Epidemiological Investigations: World Health Organisation UNITY Protocols Provide a Standardized and Timely International Investigation Framework During the COVID-19 Pandemic	Isabel	Bergeri	WHO HQ	Switzerland
181	Emergency Preparedness and Planning Training Courses; Need and Delivery During a Pandemic	Celine	Tabche	Imperial College London	United Kingdom
182	Seasonal Influenza Vaccination: Attitudes, Practices, and Perceptions of Healthcare Workers in Jordan	Olla	Hamdan	Vanderbilt University Medical Center	United States
183	Seasonal Influenza Vaccine Dose Distribution Survey - A Proxy for Global Pandemic Preparedness	Beverly	Taylor	Seqirus Vaccines	United Kingdom